 March 29, 2007
|
Green Tea for HIV?
A component of green tea blocks the ability of HIV to enter CD4 cells, according to the results of test tube studies reported by researchers in Houston and the United Kingdom.
|
|
|
| March 28, 2007
|
March 27, 2007
|
Fish Oil Lowers Lipids in HIV
Omega-3 polyunsaturated fatty acids in fish oil can lower triglyceride levels in HIV-infected patients taking antiretroviral drugs, according to a report in the March 1st Journal of Acquired Immune Deficiency Syndromes.
|
|
|
March 23, 2007
|
Poz Kids Can Maintain Stable CD4s
More than half of a cohort of children born with HIV, who never received highly active antiretroviral therapy (HAART) or received only minimal therapy, continue to maintain stable CD4 cell counts into adolescence and HIV RNA levels have declined as these children enter their teen years, according to the findings of a small study.
|
|
|
March 22, 2007
|
HPV Vaccine May Slow HIV
Human papilloma virus-like particles, non-infectious agents that have been used in vaccines against cervical cancer associated with human papilloma virus (HPV), also appear to inhibit HIV-1 replication in vitro, researchers report in the March 1st issue of Blood.
|
|
|
March 21, 2007
|
Counseling Can Reduce HIV Spread
A cognitive-behavioral intervention among people living with HIV significantly reduces the risk of HIV transmission, results of the Healthy Living Project show.
|
|
|
March 20, 2007
|
Apricitabine Useful for Drug-Resistant HIV
Avexa has announced encouraging Phase II study results involving its experimental antiretroviral apricitabine (AVX754), with evidence of activity against HIV strains resistant to Epivir (lamivudine) and Emtrvia (emtricitabine).
|
|
|
March 16, 2007
|
Sharp Drop in Hepatitis Cases
In the last decade, the number of new cases of hepatitis has fallen
dramatically in the United States, due largely to the availability of
vaccines against hepatitis A and B, the CDC reported Thursday.
|
|
|
March 15, 2007
|
Early HCV Response Predicts Outcome
Early virologic response to an interferon-based regimen plus ribavirin
for hepatitis C virus (HCV) infection predicts sustained virologic
response in patients who are also infected with HIV.
|
|
|
March 14, 2007
|
Testosterone Doesn't Build Muscle in Wasting
Testosterone supplementation of megestrol therapy produces "robust"
weight gain and preserves sexual function when given with testosterone,
but does not enhance lean tissue accrual in men with HIV-associated
weight loss, according to researchers.
|
|
|
March 09, 2007
|
Study Finds Viread Advantages in Black Patients
An analysis of two Gilead-sponsored studies suggests that black HIV-positive patients have a better chances of an undetectable viral load after 96 weeks using treatment regimens containing Viread compared to those containing the thymidine analogues Retrovir or Zerit.
|
|
|
| March 08, 2007
|
March 06, 2007
|
Twice-Daily Kaletra Possibly Better for Some Patients
An ACTG study indicates that once-daily and twice-daily Kaletra are comparable in patients over 48 weeks of treatment, but also suggests that the time to virologic failure using once-daily Kaletra may be shorter among those with high pre-treatment viral loads.
|
|
|
March 05, 2007
|
Baraclude Induces HIV Drug Resistance
New research concludes that hepatitis B virus (HBV) treatment Baraclude (entecavir) is active against HIV, suggesting that that the drug will need to be used with caution in people coinfected with both HIV and HBV.
|
|
|
March 02, 2007
|
Study Says Less Fat for Lower Lipids
While HIV meds play a role in the high rates of cholesterol and triglyceride problems being seen in HIV-positive people, it also appears that diets rich in fat are likely culprits as well.
|
|
|
March 01, 2007
|
Once-Daily Viramune Strikes Out
For several years, researchers have been looking into the possibility of once-daily Viramune dosing. New data, however, suggest that the approved twice-daily schedule will remain the necessary dosing option.
|
|
|
Still No Clear Benefit of Treating Early HIV
The long-term benefits of starting antiretroviral therapy during primary HIV infection have still not been confirmed. The conflicting results of two studies presented at the 14th CROI highlight the need to clarify this issue.
|
|
|
|
Dr. Calvin Cohen discusses Kaletra vs. Sustiva, the newly infected showing HIV drug resistance, and HIVers dying from non-AIDS cancers 
Dr. Don Kotler discusses news from CROI about lipodystrophy, bone loss, and metabolic problems 
